The normalized data was used to predict the
molecular formula based on additive ions,molecular ion peaks and fragment ions.And
then peaks were matched with the mzCloud(https://www.mzcloud.org/), mzVaultand
MassListdatabase to obtain the accuratequalitative and relative quantitative
results.Statistical analyses were performed using the statistical software R (R version
R-3.4.3),Python (Python 2.7.6 version) and CentOS(CentOS release 6.6),When data
were not normally distributed, normal transformations were attempted using of area
normalization method.
"],"repository":["MetaboLights"],"study_status":["Public"],"ptm_modification":[""],"instrument_platform":["Liquid Chromatography MS - negative - reverse-phase","Liquid Chromatography MS - positive - reverse-phase"],"chromatography_protocol":["UHPLC-MS/MS analyses were performed using a Vanquish UHPLC system
(ThermoFisher, Germany) coupled with an Orbitrap Q ExactiveTMHF-X mass
spectrometer (Thermo Fisher, Germany)in Novogene Co., Ltd. (Beijing, China).
Samples were injected onto a HypersilGoldcolumn (100×2.1 mm, 1.9μm) using a
12-min linear gradient at a flow rate of 0.2mL/min. The eluents for the positive and
negative polarity modes were eluent A (0.1% FA in Water) and eluent B
(Methanol).The solvent gradient was set as follows: 2% B, 1.5 min; 2-85% B, 3 min;
85-100% B, 10 min; 100-2% B, 10.1 min; 2% B, 12 min.
"],"publication":["LGG exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib."],"submitter_name":["丽婷 å¢"],"submitter_affiliation":["æµ·å大å¦"],"organism_part":["serum"],"technology_type":["mass spectrometry assay"],"disease":[""],"extraction_protocol":["The samples (100 μL) were placed in the EP tubes and resuspended with prechilled 80%
methanol by well vortex. Then the sampleswere incubated on ice for 5 min and
centrifuged at 15,000 g, 4°C for 20 min. Some of supernatant was diluted to final
concentration containing 53% methanol by LC-MS grade water.The samples were
subsequently transferred to a fresh Eppendorf tube and thenwere centrifuged at 15000
g, 4°C for 20 min. Finally, the supernatant was injected into the LC-MS/MS system
analysis
"],"organism":["Mus musculus"],"full_dataset_link":["https://www.ebi.ac.uk/metabolights/MTBLS13812"],"author":["Siyuan Shen. Hainan University. 1512181782@qq.com."],"data_transformation_protocol":["The raw data files generated by UHPLC-MS/MS were processed using the Compound
Discoverer 3.3 (CD3.3, ThermoFisher) to perform peak alignment, peak picking, and
quantitation for each metabolite. The main parameterswere set as follows: peak area
was corrected with the first sample; actual mass tolerance, 5ppm; signal intensity
tolerance, 30%; and minimum intensity, et al.After that, peak intensities were
normalized to the total spectral intensity.
"],"study_factor":["Treatment"],"submitter_email":["1512181782@qq.com"],"sample_collection_protocol":["Following sacrifice, blood was collected from mice and left to stand for 2 hours at room temperature to allow clotting. It was then centrifuged for 20 minutes. The upper serum layer was carefully aspirated and stored at -80°C.
"],"omics_type":["Metabolomics"],"study_design":["gefitinib","Lung Non-Small Cell Carcinoma","Lactobacillus rhamnosus","untargeted metabolite profiling"],"curator_keywords":["gefitinib","Lung Non-Small Cell Carcinoma","Lactobacillus rhamnosus","untargeted metabolite profiling"],"mass_spectrometry_protocol":["Q ExactiveTM HF mass
spectrometer was operated in positive/negative polarity mode with spray voltage of
3.5 kV, capillary temperature of 320°C, sheath gas flow rate of 35 psi and aux gas
flow rate of 10 L/min, S-lens RF level of 60, Aux gas heater temperature of 350°C.
"],"additional_accession":[]},"is_claimable":false,"name":"Lactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Serum metabolomics study in mice","description":"After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and in vitro experiments.
","dates":{"publication":"2026-09-03","submission":"2026-01-31"},"accession":"MTBLS13812","cross_references":{}}